Cardiovascular providers discuss their biggest challenges, including payers refusing to cover tests, procedures or medications that could benefit patients and providing costly and beneficial therapies and procedures while dealing with cost constraints. There are plenty more, listen in.

Cardiologists J.P. Reilly, MD, and Larry S. Dean, MD, offer insight on the two-year results of the ABSORB III trial that evaluated Abbott’s Absorb bioresorbable vascular scaffold. They also talk about the March 18th FDA advisory letter alerting healthcare professionals of an increase in major adverse cardiac events with the Absorb compared with the Xience drug-eluting stent. As they note, physicians need to be careful about selecting the right patients who may benefit from bioresorbable stents, using them in right-sized vessels and making sure to properly deploy the devices.

Several medical societies recently released updated appropriate use criteria (AUC) for coronary revascularization in patients with acute coronary syndromes (ACS).

Three leading cardiology societies released a consensus statement on Dec. 10 regarding criteria institutions and operators should follow for left atrial appendage occlusion.

Major cardiovascular societies are increasing their public reporting of data to help patients obtain information on hospitals’ care delivery and improve the quality and cost of care, according to an advisory published online in the Journal of the American College of Cardiology on Nov. 18.

Three major cardiology societies released a new guideline on Sept. 23 to manage adults with all types of supraventricular tachycardia (SVT) other than atrial fibrillation.